<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02165098</url>
  </required_header>
  <id_info>
    <org_study_id>RGH-188-101</org_study_id>
    <secondary_id>2013-004925-99</secondary_id>
    <nct_id>NCT02165098</nct_id>
  </id_info>
  <brief_title>Cariprazine: Comparison of Slow- and Immediate-release Forms</brief_title>
  <official_title>A Single-Dose Study to Evaluate the Pharmacokinetic, Safety, Tolerability Profile and the Effects of Food on the Pharmacokinetics of Different Formulations of Cariprazine in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gedeon Richter Plc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gedeon Richter Plc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are doing this study to compare blood levels and side effects of
      cariprazine when it's taken as one of two 'slow release' tablets, or as an 'immediate
      release' capsule. The investigators will also find out if food affects the absorption of
      cariprazine into the bloodstream after a 'slow release' tablet.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Comparison of blood levels and side effects of cariprazine when it's taken as one of two
      'slow release' tablets, or as an 'immediate release' capsule. We'll also find out if food
      affects the absorption of cariprazine into the bloodstream after a 'slow release' tablet.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>C[max]</measure>
    <time_frame>0-672 hours</time_frame>
    <description>Maximum Serum Concentration of the parent drug</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>0-672 hours</time_frame>
    <description>Area Under the Serum Concentration-Time Curve of the parent drug</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T[max]</measure>
    <time_frame>0-672 hours</time_frame>
    <description>Time to Reach the Maximum Serum Concentration of the parent drug</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other PK parameters of the parent drug</measure>
    <time_frame>0-672 hours</time_frame>
    <description>Elimination half-life period (t1/2), Mean Residence Time (MRT), if applicable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of the metabolites, if applicable</measure>
    <time_frame>0-672 hours</time_frame>
    <description>Maximum Serum Concentration (Cmax), Time to Reach the Maximum Serum Concentration (Tmax), (AUC0-t), Area Under the Serum Concentration-Time Curve From Time Zero to Infinite Time (AUC0-∞), Elimination half-life period (t1/2) and Mean Residence Time (MRT)</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Pharmacokinetic Profile</condition>
  <arm_group>
    <arm_group_label>Cariprazine PR tablet B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cariprazine prolonged release tablet B - fed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cariprazine PR tablet A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cariprazine prolonged release tablet A - fed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cariprazine capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cariprazine capsule - fasted</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cariprazine prolonged release tablet B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cariprazine prolonged release tablet B - fasted</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cariprazine prolonged release tablet A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cariprazine prolonged release tablet A - fasted</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cariprazine prolonged release tablet A</intervention_name>
    <description>Cariprazine prolonged release tablet A - fasted</description>
    <arm_group_label>Cariprazine prolonged release tablet A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cariprazine prolonged release tablet B</intervention_name>
    <description>Cariprazine prolonged release tablet B - fasted</description>
    <arm_group_label>Cariprazine prolonged release tablet B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cariprazine capsule</intervention_name>
    <description>Cariprazine capsule - fasted</description>
    <arm_group_label>Cariprazine capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cariprazine PR tablet A</intervention_name>
    <description>Cariprazine Prolonged Release tablet A - fed</description>
    <arm_group_label>Cariprazine PR tablet A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cariprazine PR tablet B</intervention_name>
    <description>Cariprazine Prolonged Release tablet B - fed</description>
    <arm_group_label>Cariprazine PR tablet B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Caucasian males aged 18-55 years with body mass index (BMI) ≥ 18 kg/m2 and ≤
             30 kg/m2

          -  Have a semisupine pulse rate ≥ 40 bpm and ≤ 100 bpm during the vital sign assessment
             at screening and on admission (Day 1)

          -  Agree to use an effective method of contraception and not have their partners become
             pregnant throughout the study and for up to 4 months after the administration of the
             IMP, or have been sterilized for at least 1 year

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hammersmith Medicines Research</name>
      <address>
        <city>London</city>
        <zip>NW10 7EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2014</study_first_submitted>
  <study_first_submitted_qc>June 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2014</study_first_posted>
  <last_update_submitted>March 23, 2016</last_update_submitted>
  <last_update_submitted_qc>March 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

